ETONITAZENE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C22H28N4O3
Molecular Weight	396.4827
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCOC1=CC=C(CC2=NC3=C(C=CC(=C3)[N+]([O-])=O)N2CCN(CC)CC)C=C1

InChI

InChIKey=PXDBZSCGSQSKST-UHFFFAOYSA-N

InChI=1S/C22H28N4O3/c1-4-24(5-2)13-14-25-21-12-9-18(26(27)28)16-20(21)23-22(25)15-17-7-10-19(11-8-17)29-6-3/h7-12,16H,4-6,13-15H2,1-3H3

HIDE SMILES / InChI

Molecular Formula	C22H28N4O3
Molecular Weight	396.4827
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2167979 | https://www.ncbi.nlm.nih.gov/pubmed/4961975 | https://www.unodc.org/pdf/convention_1961_en.pdf

Etonitazene is a potent and selective mu-opioid agonist. It was developed in CIBA. Administration of etonitazene may induce respiratory depression, and therefor etonitazene is not used in humans. Etonitazene is explicitly listed as an illegal drug under UN convention and is illegal throughout the world.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Mu opioid receptor 221 Target ID: CHEMBL233 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2167979	Agonist 2678		0.5 nM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Pain 614 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2167979	Primary		Preclinical	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Photoactivatable opiate derivatives as irreversible probes of the mu-opioid receptor.	1990 Sep	2167979
Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications.	1998 Mar	9686407
Intravenous self-administration of etonitazene alone and combined with cocaine in rhesus monkeys: comparison with heroin and antagonism by naltrexone and naloxonazine.	2009 Jun	19225763
Analgesic tolerance to high-efficacy agonists but not to morphine is diminished in phosphorylation-deficient S375A μ-opioid receptor knock-in mice.	2011 Sep 28	21957251

Patents

Sample Use Guides

In Vivo Use Guide

In rat tail-withdrawal assay, etonitazene was administered subcutaneously. ED50 was 0.38 mg/kg.

Route of Administration: Other

In Vitro Use Guide

Binding of etonitazene to mu-opioid receptors from the membrane fraction of rat brains (minus cerebellum) was studied using [3H]DAMGO as a radioligand. Etonitazene binds to mu-opioid receptors with Ki of 0.5 nM.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:10:57 UTC 2023` Edited by `admin` on `Fri Dec 15 16:10:57 UTC 2023`
Record UNII	9U3GT3353T
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ETONITAZENE

Official Name

English

1-(2-DIETHYLAMINOETHYL)-2-(P-ETHOXYBENZYL)-5-NITROBENZIMIDAZOLE

Common Name

English

ETONITAZENE [MI]

Common Name

English

etonitazene [INN]

Common Name

English

1H-BENZIMIDAZOLE-1-ETHANAMINE, 2-((4-ETHOXYPHENYL)METHYL)-N,N-DIETHYL-5-NITRO-

Systematic Name

English

CIBA 20-684BA

Common Name

English

ARC 1G2

Common Name

English

BA-20684

Code

English

NIH 7607

Code

English

NIH-7607

Code

English

IDS-NE-006

Code

English

ETOBEDOLUM

Common Name

English

ACSCN-9624

Common Name

English

Etonitazene [WHO-DD]

Common Name

English

ETONITAZINE

Common Name

English

Classification Tree Code System Code

DEA NO.

9624